Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Anshuman Swain

Pain Medicine Logan, OH Medical Doctor

NPI 1669698544 CMS profile 257643

819 State Route 664 N Ste B, Logan, OH 43138

Open in the dashboard

General payments

$29,891

325 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Anshuman Swain of Logan, OH is reported in the CMS Open Payments database as having received $29,891 across 325 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $6,113 43
2024 General $10,158 80
2023 General $4,299 52
2022 General $3,528 62
2021 General $1,753 35
2020 General $1,613 36
2019 General $2,428 17

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Anshuman Swain
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Anshuman Swain were reported at $6,113. Among 2,779 Pain Medicine profiles paid that year, the median was $458 and the middle half received between $124 and $1,401.

Show as a table
Year Anshuman Swain Pain Medicine median Middle half National median
2019 $2,428 $498 $126–$1,682 $163
2020 $1,613 $284 $80–$910 $114
2021 $1,753 $399 $112–$1,219 $132
2022 $3,528 $455 $137–$1,484 $149
2023 $4,299 $484 $128–$1,495 $160
2024 $10,158 $498 $131–$1,540 $164
2025 $6,113 $458 $124–$1,401 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Nalu Medical, Inc. $12,880 94 payments
  2. Stratus Medical, LLC $7,925 90 payments
  3. Abbott Laboratories $1,862 23 payments
  4. Vertos Medical, Inc. $1,733 21 payments
  5. Boston Scientific Corporation $1,601 57 payments
  6. Vertiflex, Inc. $1,570 8 payments
  7. Stryker Corporation $744 6 payments
  8. Respicardia, Inc. $516 2 payments
  9. BIOTRONIK NRO, Inc. $386 9 payments
  10. Veryan Medical Incorporated $248 1 payment
  11. Other $428 14 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $17,861 302 payments
  2. Travel and Lodging $7,461 16 payments
  3. Consulting Fee $4,500 6 payments
  4. Education $70 1 payment
Products named General payments · program years 2019–2025
  1. Nalu Neurostimulation System $12,880 94 payments
  2. Nimbus $7,925 90 payments
  3. Superion ISS $1,570 8 payments
  4. mild Device Kit Orthopedic $1,131 16 payments
  5. Superion Indirect Decompression System $994 13 payments
  6. PROCLAIM Neuromodulation $675 4 payments
  7. PROCLAIM Neuromodulation $620 3 payments
  8. mild Device Kit Orthopedic $602 5 payments
  9. remede System $516 2 payments
  10. MILD DEVICE KIT Instruments $398 3 payments
  11. Other $2,573 81 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 34 drugs

Part D claims

6,848

Median for Pain Management: 951

Drug cost

$278,793

Median for Pain Management: $26,034

Branded share of claims

49.5%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycontin Oxycodone Hcl Brand 110 $87,160
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 1,874 $60,581
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 1,190 $29,795
Oxycodone Hcl Generic 934 $22,816
Nucynta Er Tapentadol Hcl Brand 12 $14,496
Pregabalin Generic 265 $11,522
Gabapentin Generic 680 $10,472
Naloxone Hcl Generic 189 $10,055
Buprenorphine Generic 30 $7,684
Fentanyl Generic 29 $3,705

The 10 drugs with the highest cost, of 34 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 13 billing codes

Paid by Medicare

$1,895

Medicare's payments for the services billed

Medicare patients

13

Average age 57

Services billed

23

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Atrial fibrillation 0%
Chronic kidney disease 0%
Osteoporosis 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

325 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record